Presentation is loading. Please wait.

Presentation is loading. Please wait.

Baseline Characteristics of 987 Individuals With Stable Coronary Heart Disease by Amino Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide.

Published byAugustine Shelton Modified over 8 years ago

Similar presentations

Presentation on theme: "Baseline Characteristics of 987 Individuals With Stable Coronary Heart Disease by Amino Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide."— Presentation transcript:

1 Baseline Characteristics of 987 Individuals With Stable Coronary Heart Disease by Amino Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) Quartile* Kirsten Bibbins-Domingo, et al. JAMA 2007;297:169-176

2 Baseline Measures of Other Known Prognostic Markers by Amino Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) Quartile Among 987 Individuals With Stable Coronary Heart Disease* Kirsten Bibbins-Domingo, et al. JAMA 2007;297:169-176

3 Survival Free of Cardiovascular Events or Death by NT-proBNP Quartile Kirsten Bibbins-Domingo, et al. JAMA 2007;297:169-176

4 Adverse Cardiovascular Outcomes by Quartile of Amino Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP)* Kirsten Bibbins-Domingo, et al. JAMA 2007;297:169-176

5 Association of NT-proBNP With Any Cardiovascular Event or Death After Adjusting for Available Prognostic Markers Kirsten Bibbins-Domingo, et al. JAMA 2007;297:169-176

6 Association of Log Amino Terminal Fragment of the Prohormone Brain- Type Natriuretic Peptide (NT-proBNP) per 1 SD Increase With Specific Cardiovascular Outcomes After Adjusting for Other Prognostic Markers Kirsten Bibbins-Domingo, et al. JAMA 2007;297:169-176

7 Association of Various Cut Points of Amino Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) Cardiovascular Events or Death Kirsten Bibbins-Domingo, et al. JAMA 2007;297:169-176

Download ppt "Baseline Characteristics of 987 Individuals With Stable Coronary Heart Disease by Amino Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide."

Similar presentations

Literature Search Strategy Used for the MEDLINE Database Gami AS, et al. J Am Coll Cardiol 2007;49:403-14.

Literature Search Strategy Used for the MEDLINE Database Gami AS, et al. J Am Coll Cardiol 2007;49:
Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):1943-1950.

Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):
Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]
Trial profile Fox K et al. Lancet 2008;372:807-16.

Trial profile Fox K et al. Lancet 2008;372:
PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Prognostic.

PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Prognostic.
Prognostic Utility of Secretory Phospholipase A 2 in Patients with Stable Coronary Artery Disease M. O'Donoghue, Z. Mallat, D.A. Morrow, J. Benessiano,

Prognostic Utility of Secretory Phospholipase A 2 in Patients with Stable Coronary Artery Disease M. O'Donoghue, Z. Mallat, D.A. Morrow, J. Benessiano,
Baseline Characteristics of Individuals From the General Population by Quartiles of Triglyceride Levels a Børge G. Nordestgaard, et al. JAMA 2007;298:299-308.

Baseline Characteristics of Individuals From the General Population by Quartiles of Triglyceride Levels a Børge G. Nordestgaard, et al. JAMA 2007;298:
Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:1338- 1347.

Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:
Ho PM, et al. JAMA 2009;301:937-44. Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:937-44.

Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:
Lancet 373:1765-72, 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:131-40.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
The ILLUMINATE Study: Enrollment and Outcomes Philip Barter, et al. N Engl J Med 2007;357:2109-22.

The ILLUMINATE Study: Enrollment and Outcomes Philip Barter, et al. N Engl J Med 2007;357:
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13):1340-1349. ?

Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
Charlotte Kragelund et al N Engl J Med 2005;352:666- 75 Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.

Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.
Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:129-139.

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:
Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:306-313.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Prognostic Value of N-Terminal Pro–B-Type Natriuretic.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Prognostic Value of N-Terminal Pro–B-Type Natriuretic.
Prognostic Value of B-Type Natriuretic Peptides in Patients with Stable Coronary Artery Disease The PEACE trial Omland T, et al. JACC 2007;50:205-14.

Prognostic Value of B-Type Natriuretic Peptides in Patients with Stable Coronary Artery Disease The PEACE trial Omland T, et al. JACC 2007;50:
Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial Torbjørn Omland, MD, PHD, MPH, Marc S.

Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial Torbjørn Omland, MD, PHD, MPH, Marc S.
The Association of Five-Year Changes in the Levels of N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) with Subsequent.

The Association of Five-Year Changes in the Levels of N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) with Subsequent.

Similar presentations

Ads by Google